Britain’s National Institute for Health and Clinical Excellence has recommended apixaban for the prevention of stroke and systemic embolism in some people with atrial fibrillation.
Aapixaban is a direct Xa inhibitor, and so does not require regular blood tests to monitor the blood’s clotting properties, unlike the most commonly used antithrombotic, warfarin.